
Previous phase 3 studies have demonstrated the efficacy of nebulized glycopyrrolate inhalation solution (GLY) for treating patients with chronic obstructive pulmonary disease (COPD). In a recent study, researchers conducted a secondary analysis and found that nebulized GLY demonstrated efficacy and was well tolerated for up to 48 weeks in subjects with COPD with or without background long-acting beta2-agonist (LABA).